Cytek Biosciences Inc (CTKB)vsEdwards Lifesciences Corp (EW)
CTKB
Cytek Biosciences Inc
$4.31
-1.60%
HEALTHCARE · Cap: $588.89M
EW
Edwards Lifesciences Corp
$86.92
+1.35%
HEALTHCARE · Cap: $49.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 2987% more annual revenue ($6.30B vs $204.17M). EW leads profitability with a 17.4% profit margin vs -36.2%. EW earns a higher WallStSmart Score of 61/100 (C+).
CTKB
Hold41
out of 100
Grade: D
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.3%
Fair Value
$7.43
Current Price
$4.31
$3.12 discount
Margin of Safety
+68.2%
Fair Value
$249.70
Current Price
$86.92
$162.78 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
Smaller company, higher risk/reward
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Altman Z-Score, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while EW is a growth play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.17 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
CTKB generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 41/100), backed by strong 17.4% margins and 16.7% revenue growth. CTKB offers better value entry with a 41.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?